Managing high-risk CLL during transition to a new treatment era

Stem cell transplantation or novel agents?

Peter Dreger, Johannes Schetelig, Niels Andersen, Paolo Corradini, Michel Van Gelder, John Gribben, Eva Kimby, Mauricette Michallet, Carol Moreno, Stephan Stilgenbauer, Emili Montserrat

Research output: Contribution to journal › Article

126 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [

Original languageEnglish
Pages (from-to)3841-3849
Number of pages9
JournalBlood
Volume124
Issue number26
DOIs
Publication statusPublished - Dec 18 2014

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
B-Cell Chronic Lymphocytic Leukemia
Stem cells
Refractory materials
Therapeutics
purine

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Dreger, P., Schetelig, J., Andersen, N., Corradini, P., Van Gelder, M., Gribben, J., ... Montserrat, E. (2014). Managing high-risk CLL during transition to a new treatment era: Stem cell transplantation or novel agents? Blood, 124(26), 3841-3849. https://doi.org/10.1182/blood-2014-07-586826

Managing high-risk CLL during transition to a new treatment era : Stem cell transplantation or novel agents? / Dreger, Peter; Schetelig, Johannes; Andersen, Niels; Corradini, Paolo; Van Gelder, Michel; Gribben, John; Kimby, Eva; Michallet, Mauricette; Moreno, Carol; Stilgenbauer, Stephan; Montserrat, Emili.

In: Blood, Vol. 124, No. 26, 18.12.2014, p. 3841-3849.

Research output: Contribution to journal › Article

Dreger, P, Schetelig, J, Andersen, N, Corradini, P, Van Gelder, M, Gribben, J, Kimby, E, Michallet, M, Moreno, C, Stilgenbauer, S & Montserrat, E 2014, 'Managing high-risk CLL during transition to a new treatment era: Stem cell transplantation or novel agents?', Blood, vol. 124, no. 26, pp. 3841-3849. https://doi.org/10.1182/blood-2014-07-586826
Dreger P, Schetelig J, Andersen N, Corradini P, Van Gelder M, Gribben J et al. Managing high-risk CLL during transition to a new treatment era: Stem cell transplantation or novel agents? Blood. 2014 Dec 18;124(26):3841-3849. https://doi.org/10.1182/blood-2014-07-586826
Dreger, Peter ; Schetelig, Johannes ; Andersen, Niels ; Corradini, Paolo ; Van Gelder, Michel ; Gribben, John ; Kimby, Eva ; Michallet, Mauricette ; Moreno, Carol ; Stilgenbauer, Stephan ; Montserrat, Emili. / Managing high-risk CLL during transition to a new treatment era : Stem cell transplantation or novel agents?. In: Blood. 2014 ; Vol. 124, No. 26. pp. 3841-3849.
@article{8e4778973be34e64a065740616b5760c,
title = "Managing high-risk CLL during transition to a new treatment era: Stem cell transplantation or novel agents?",
abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [",
author = "Peter Dreger and Johannes Schetelig and Niels Andersen and Paolo Corradini and {Van Gelder}, Michel and John Gribben and Eva Kimby and Mauricette Michallet and Carol Moreno and Stephan Stilgenbauer and Emili Montserrat",
year = "2014",
month = "12",
day = "18",
doi = "10.1182/blood-2014-07-586826",
language = "English",
volume = "124",
pages = "3841--3849",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "26",

}

TY - JOUR

T1 - Managing high-risk CLL during transition to a new treatment era

T2 - Stem cell transplantation or novel agents?

AU - Dreger, Peter

AU - Schetelig, Johannes

AU - Andersen, Niels

AU - Corradini, Paolo

AU - Van Gelder, Michel

AU - Gribben, John

AU - Kimby, Eva

AU - Michallet, Mauricette

AU - Moreno, Carol

AU - Stilgenbauer, Stephan

AU - Montserrat, Emili

PY - 2014/12/18

Y1 - 2014/12/18

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [

UR - http://www.scopus.com/inward/record.url?scp=84919469417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919469417&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-07-586826

DO - 10.1182/blood-2014-07-586826

M3 - Article

VL - 124

SP - 3841

EP - 3849

JO - Blood

JF - Blood

SN - 0006-4971

IS - 26

ER -

Access to Document